N-803/BCG Approval Signals Paradigm Shift in Management of BCG-Unresponsive NMIBC
OncLive,
Karim Chamie, MD The FDA’s approval of nogapendekin alfa inbakicept-pmln (Anktiva; N-803) plus Bacillus Calmette–Guérin (BCG…
FDA Approves New Type of Immunotherapy for Early Bladder Cancer
Real Health,
Anktiva, an IL-15 agonist, also shows promise for other malignancies, including non-small-cell lung cancer, and even HIV.
FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after research shows improved outcomes for patients - ecancer
ecancer,
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, to be used in combination with…
News Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Cancer FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients.
Technology Networks,
Listen with Speechify Register for free to listen to this article Thank you. Listen to this article using the player above.